Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES)

PathIES

M C U Cheang, J M Bliss, G Viale, V Speirs, C Palmieri, A Shaaban, P E Lønning, J Morden, N Porta, J Jassem, C J van De Velde, B B Rasmussen, D Verhoeven, J M S Bartlett, R C Coombes, PathIES Sub-Committee

Research output: Contribution to journalArticle

5 Downloads (Pure)

Abstract

BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This PathIES aimed to assess the role of immunohistochemical (IHC)4 score in determining the relative sensitivity to either tamoxifen or sequential treatment with tamoxifen and exemestane.

PATIENTS AND METHODS: Primary tumour samples were available for 1274 patients (27% of IES population). Only patients for whom the IHC4 score could be calculated (based on oestrogen receptor, progesterone receptor, HER2 and Ki67) were included in this analysis (N = 430 patients). The clinical score (C) was based on age, grade, tumour size and nodal status. The association of clinicopathological parameters, IHC4(+C) scores and treatment effect with time to distant recurrence-free survival (TTDR) was assessed in univariable and multivariable Cox regression analyses. A modified clinical score (PathIEscore) (N = 350) was also estimated.

RESULTS: Our results confirm the prognostic importance of the original IHC4, alone and in conjunction with clinical scores, but no significant difference with treatment effects was observed. The combined IHC4 + Clinical PathIES score was prognostic for TTDR (P < 0.001) with a hazard ratio (HR) of 5.54 (95% CI 1.29-23.70) for a change from 1st quartile (Q1) to Q1-Q3 and HR of 15.54 (95% CI 3.70-65.24) for a change from Q1 to Q4.

CONCLUSION: In the PathIES population, the IHC4 score is useful in predicting long-term relapse in patients who remain disease-free after 2-3 years. This is a first trial to suggest the extending use of IHC4+C score for prognostic indication for patients who have switched endocrine therapies at 2-3 years and who remain disease-free after 2-3 years.

Original languageEnglish
Pages (from-to)169-178
Number of pages10
JournalBreast Cancer Research and Treatment
Volume168
Issue number1
Early online date24 Nov 2017
DOIs
Publication statusPublished - Feb 2018

Fingerprint

exemestane
Tamoxifen
Recurrence
Survival
Therapeutics
Progesterone Receptors
Estrogen Receptors
Population
Neoplasms
Regression Analysis

Keywords

  • Journal Article
  • breast cancer
  • aromatase
  • prognosis

Cite this

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES) : PathIES. / Cheang, M C U; Bliss, J M; Viale, G; Speirs, V; Palmieri, C; Shaaban, A; Lønning, P E; Morden, J; Porta, N; Jassem, J; van De Velde, C J; Rasmussen, B B; Verhoeven, D; Bartlett, J M S; Coombes, R C; PathIES Sub-Committee.

In: Breast Cancer Research and Treatment, Vol. 168, No. 1, 02.2018, p. 169-178.

Research output: Contribution to journalArticle

Cheang, MCU, Bliss, JM, Viale, G, Speirs, V, Palmieri, C, Shaaban, A, Lønning, PE, Morden, J, Porta, N, Jassem, J, van De Velde, CJ, Rasmussen, BB, Verhoeven, D, Bartlett, JMS, Coombes, RC & PathIES Sub-Committee 2018, 'Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES', Breast Cancer Research and Treatment, vol. 168, no. 1, pp. 169-178. https://doi.org/10.1007/s10549-017-4543-7
Cheang, M C U ; Bliss, J M ; Viale, G ; Speirs, V ; Palmieri, C ; Shaaban, A ; Lønning, P E ; Morden, J ; Porta, N ; Jassem, J ; van De Velde, C J ; Rasmussen, B B ; Verhoeven, D ; Bartlett, J M S ; Coombes, R C ; PathIES Sub-Committee. / Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES) : PathIES. In: Breast Cancer Research and Treatment. 2018 ; Vol. 168, No. 1. pp. 169-178.
@article{e749d8cb67004760ad9d32dc2101a369,
title = "Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES",
abstract = "BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This PathIES aimed to assess the role of immunohistochemical (IHC)4 score in determining the relative sensitivity to either tamoxifen or sequential treatment with tamoxifen and exemestane.PATIENTS AND METHODS: Primary tumour samples were available for 1274 patients (27{\%} of IES population). Only patients for whom the IHC4 score could be calculated (based on oestrogen receptor, progesterone receptor, HER2 and Ki67) were included in this analysis (N = 430 patients). The clinical score (C) was based on age, grade, tumour size and nodal status. The association of clinicopathological parameters, IHC4(+C) scores and treatment effect with time to distant recurrence-free survival (TTDR) was assessed in univariable and multivariable Cox regression analyses. A modified clinical score (PathIEscore) (N = 350) was also estimated.RESULTS: Our results confirm the prognostic importance of the original IHC4, alone and in conjunction with clinical scores, but no significant difference with treatment effects was observed. The combined IHC4 + Clinical PathIES score was prognostic for TTDR (P < 0.001) with a hazard ratio (HR) of 5.54 (95{\%} CI 1.29-23.70) for a change from 1st quartile (Q1) to Q1-Q3 and HR of 15.54 (95{\%} CI 3.70-65.24) for a change from Q1 to Q4.CONCLUSION: In the PathIES population, the IHC4 score is useful in predicting long-term relapse in patients who remain disease-free after 2-3 years. This is a first trial to suggest the extending use of IHC4+C score for prognostic indication for patients who have switched endocrine therapies at 2-3 years and who remain disease-free after 2-3 years.",
keywords = "Journal Article, breast cancer, aromatase, prognosis",
author = "Cheang, {M C U} and Bliss, {J M} and G Viale and V Speirs and C Palmieri and A Shaaban and L{\o}nning, {P E} and J Morden and N Porta and J Jassem and {van De Velde}, {C J} and Rasmussen, {B B} and D Verhoeven and Bartlett, {J M S} and Coombes, {R C} and {PathIES Sub-Committee}",
note = "This work was supported by Cancer Research UK (C37/A8434) and Pfzer (GA9001DP). Cancer Research UK also providedprogramme grants to the Institute of Cancer Research Clinical Trials and Statistics Unit and the Division of Cancer at Imperial College London. This study was supported by Imperial Experimental Cancer Medicine Centre, Imperial Biomedical Research Centre and Imperial Cancer Research UK Centre. MCUC is supported by the Cancer Research UK Core grant (Grant Number C1491/A15955).",
year = "2018",
month = "2",
doi = "10.1007/s10549-017-4543-7",
language = "English",
volume = "168",
pages = "169--178",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES)

T2 - PathIES

AU - Cheang, M C U

AU - Bliss, J M

AU - Viale, G

AU - Speirs, V

AU - Palmieri, C

AU - Shaaban, A

AU - Lønning, P E

AU - Morden, J

AU - Porta, N

AU - Jassem, J

AU - van De Velde, C J

AU - Rasmussen, B B

AU - Verhoeven, D

AU - Bartlett, J M S

AU - Coombes, R C

AU - PathIES Sub-Committee

N1 - This work was supported by Cancer Research UK (C37/A8434) and Pfzer (GA9001DP). Cancer Research UK also providedprogramme grants to the Institute of Cancer Research Clinical Trials and Statistics Unit and the Division of Cancer at Imperial College London. This study was supported by Imperial Experimental Cancer Medicine Centre, Imperial Biomedical Research Centre and Imperial Cancer Research UK Centre. MCUC is supported by the Cancer Research UK Core grant (Grant Number C1491/A15955).

PY - 2018/2

Y1 - 2018/2

N2 - BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This PathIES aimed to assess the role of immunohistochemical (IHC)4 score in determining the relative sensitivity to either tamoxifen or sequential treatment with tamoxifen and exemestane.PATIENTS AND METHODS: Primary tumour samples were available for 1274 patients (27% of IES population). Only patients for whom the IHC4 score could be calculated (based on oestrogen receptor, progesterone receptor, HER2 and Ki67) were included in this analysis (N = 430 patients). The clinical score (C) was based on age, grade, tumour size and nodal status. The association of clinicopathological parameters, IHC4(+C) scores and treatment effect with time to distant recurrence-free survival (TTDR) was assessed in univariable and multivariable Cox regression analyses. A modified clinical score (PathIEscore) (N = 350) was also estimated.RESULTS: Our results confirm the prognostic importance of the original IHC4, alone and in conjunction with clinical scores, but no significant difference with treatment effects was observed. The combined IHC4 + Clinical PathIES score was prognostic for TTDR (P < 0.001) with a hazard ratio (HR) of 5.54 (95% CI 1.29-23.70) for a change from 1st quartile (Q1) to Q1-Q3 and HR of 15.54 (95% CI 3.70-65.24) for a change from Q1 to Q4.CONCLUSION: In the PathIES population, the IHC4 score is useful in predicting long-term relapse in patients who remain disease-free after 2-3 years. This is a first trial to suggest the extending use of IHC4+C score for prognostic indication for patients who have switched endocrine therapies at 2-3 years and who remain disease-free after 2-3 years.

AB - BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This PathIES aimed to assess the role of immunohistochemical (IHC)4 score in determining the relative sensitivity to either tamoxifen or sequential treatment with tamoxifen and exemestane.PATIENTS AND METHODS: Primary tumour samples were available for 1274 patients (27% of IES population). Only patients for whom the IHC4 score could be calculated (based on oestrogen receptor, progesterone receptor, HER2 and Ki67) were included in this analysis (N = 430 patients). The clinical score (C) was based on age, grade, tumour size and nodal status. The association of clinicopathological parameters, IHC4(+C) scores and treatment effect with time to distant recurrence-free survival (TTDR) was assessed in univariable and multivariable Cox regression analyses. A modified clinical score (PathIEscore) (N = 350) was also estimated.RESULTS: Our results confirm the prognostic importance of the original IHC4, alone and in conjunction with clinical scores, but no significant difference with treatment effects was observed. The combined IHC4 + Clinical PathIES score was prognostic for TTDR (P < 0.001) with a hazard ratio (HR) of 5.54 (95% CI 1.29-23.70) for a change from 1st quartile (Q1) to Q1-Q3 and HR of 15.54 (95% CI 3.70-65.24) for a change from Q1 to Q4.CONCLUSION: In the PathIES population, the IHC4 score is useful in predicting long-term relapse in patients who remain disease-free after 2-3 years. This is a first trial to suggest the extending use of IHC4+C score for prognostic indication for patients who have switched endocrine therapies at 2-3 years and who remain disease-free after 2-3 years.

KW - Journal Article

KW - breast cancer

KW - aromatase

KW - prognosis

U2 - 10.1007/s10549-017-4543-7

DO - 10.1007/s10549-017-4543-7

M3 - Article

VL - 168

SP - 169

EP - 178

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -